Extended-Release Drugs Market To Witness 13% CAGR Growth Through 2030: Key Industry Drivers
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Extended-Release Drugs Market Revenue Growth On Track For A 13% CAGR Through 2030
The extended-release drugs market has observed rapid expansion in recent years. Projections indicate its value will escalate from $69.63 billion in 2025 to $77.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.9%. Historically, this growth can be linked to the increasing prevalence of chronic diseases, the demand for patient-centric drug formulations, the limitations of immediate-release drugs, rising healthcare expenditure, and advancements in pharmaceutical excipients.
The extended-release drugs market is projected to experience substantial expansion in the coming years. It will grow to $126.89 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. This anticipated growth during the forecast period is largely due to factors such as the development of precision medicine, the growing acceptance of oral controlled-release formulations, the expansion of hospital and retail pharmacy networks, an increasing elderly population, and investments in new delivery technologies. Key trends anticipated within this period include tailored dosage regimens, sophisticated drug delivery systems, efforts to improve patient adherence, innovative formulation technologies, and the use of extended-release combination therapies.
Get A Free Sample Report With In-Depth Market Insights:
Extended-Release Drugs Market Growth Backed By Core Demand Fundamentals
The anticipated rise in the occurrence of chronic conditions is poised to stimulate the expansion of the extended-release drug market in the future. Chronic conditions are defined as ailments lasting for a year or more, necessitating continuous medical attention, limiting daily activities, or both. Examples include heart disease, cancer, obesity, and diabetes. Extended-release drug delivery systems are engineered to deliver a relatively constant concentration of medication in the body over an extended duration. This design helps maintain a consistent therapeutic effect and prevents the fluctuations in drug levels that can arise with immediate-release medications. For instance, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected that by the year 2050, the count of individuals aged 50 years and older experiencing at least one chronic illness would increase by 99.5%, amounting to 142.66 million. Thus, the escalating incidence of chronic conditions is a key driver for the growth of the extended-release drug market.
Extended-Release Drugs Market Segment Analysis: What Are The Core Market Categories?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Extended-Release Drugs Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the extended-release drugs market are actively developing innovative products, including next-generation extended-release tablets, to enhance their offerings and secure a competitive edge. Extended-release tablets represent a pharmaceutical design crafted to gradually release their active ingredients over an extended duration. As an illustration, in February 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults suffering from chorea and tardive dyskinesia linked to Huntington disease. It is available in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients affected by tardive dyskinesia and Huntington disease chorea now have access to another efficient treatment option. This allows individuals to manage these disorders, with the medication administered once daily. The development of austedo XR, which offers a practical and effective therapeutic alternative for those with certain movement disorders, signifies a substantial advancement in the management of these ailments.
Extended-Release Drugs Market Top Companies Driving Competitive Growth
Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.
View The Full Extended-Release Drugs Market Report:
Extended-Release Drugs Market Regional Analysis And Top Geography
North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
